Can Metformin taken early lower the risk of long COVID?
Metformin prescribed within six days of COVID diagnosis was linked to a 53% lower risk of long COVID or death over six months.
Researchers used US electronic health records to compare two groups. One included 248 people newly prescribed Metformin, a medicine used to manage blood sugar. The other included 248 people prescribed other drugs being tested for COVID. Both groups received prescriptions within six days of diagnosis. Most people in the study had the Omicron version of the virus.
The team tracked long COVID or death together as one outcome. Long COVID means new symptoms or worsening health conditions after infection. The 53% figure applies to that combined outcome, not each one separately. The supplied report does not give event counts for either group. That means we cannot tell how many fewer people were affected.
This was a comparison of existing records, not a test assigning treatments by chance. It shows a link, but cannot prove the medicine caused the lower risk. It also studied new prescriptions soon after diagnosis. It does not answer whether taking the medicine long-term offers the same benefit.
For BioSocial members, timing is a useful detail when comparing recovery notes. A medication start date, infection date, and symptom timeline add context to personal numbers. Members tracking Fasting Blood Glucose can keep those results alongside recovery notes. But this report does not show whether blood sugar changes explain the finding. Community comparisons can help describe experiences without proving what caused them.
What did your recovery look like after COVID while taking Metformin, and what dates or numbers did you track?


Comments
No comments yet.